CB1 and CB2 Cannabinoid Receptor Agonists Induce Peripheral Antinociception by Activation of the Endogenous Noradrenergic System | Zendy

Thiago Roberto Lima Romero | Zendy; Lívia C. Resende | Zendy; Luciana S. Guzzo | Zendy; Igor Dimitri Gama Duarte | Zendy

Open Access

CB1 and CB2 Cannabinoid Receptor Agonists Induce Peripheral Antinociception by Activation of the Endogenous Noradrenergic System

Author(s) -

Thiago Roberto Lima Romero,

Lívia C. Resende,

Luciana S. Guzzo,

Igor Dimitri Gama Duarte

Publication year - 2013

Publication title -

anesthesia and analgesia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 1.404

H-Index - 201

eISSN - 1526-7598

pISSN - 0003-2999

DOI - 10.1213/ane.0b013e3182707859

Subject(s) - am251 , anandamide , cannabinoid , cannabinoid receptor , pharmacology , yohimbine , cannabinoid receptor type 2 , antagonist , prazosin , medicine , endocannabinoid system , rauwolscine , receptor antagonist , chemistry , receptor

Cannabinoid agonists induce norepinephrine release in central, spinal, and peripheral sites. Previous studies suggest an interaction between the cannabinoid and adrenergic systems on antinociception. In this study, we sought to verify whether the CB1 and CB2 cannabinoid receptor agonists anandamide and N-palmitoyl-ethanolamine (PEA), respectively, are able to induce peripheral antinociception via an adrenergic mechanism.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research